BillionToOne

BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.

BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.

BillionToOne headquartered in United States, North America, operates in the Biotechnology, Medical, Genetics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $61.3B in funding across 144 round(s). With a team of 101-250 employees, BillionToOne is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - BillionToOne, raised $2.4M. Discover more about their projects, partnerships, and impact on our platform.